Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA CAR-T Therapy in CEA-positive Advanced Malignant Solid Tumors
NCT05396300Phase 1Completed
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PTC13 in colorectal cancer (CRC), gastric cancer (GC) and solid tumor (3 arms). Primary endpoints: Incidence of Adverse Events at 28 days and Maximum Tolerated Dose at 28 days. Started May 2022; status: completed.
02
Drugs
PTC13
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)solid tumor
Beyond the preview
Go deeper on NCT05396300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396300.